UBS/CALL/ELI LILLY & CO/750.001/0.01/20.12.24 | Market Closed - Swiss Exchange 08:50:00 27/05/2024 pm IST | ||
| 1.15 CHF | +0.88% |
|
| Current month | +23.66% | ||
| 1 month | +47.44% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 27/24/27 | 1.15 | +0.88% |
| 23/24/23 | 1.14 | +4.59% |
| 22/24/22 | 1.09 | -1.80% |
Delayed Quote Swiss Exchange
Last update May 27, 2024 at 08:50 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | UBS |
| LLYI8U | |
| ISIN | CH1342499048 |
| Date issued | 22/04/2024 |
| Strike | 750 $ |
| Maturity | 20/12/2024 (207 Days) |
| Parity | 100 : 1 |
| Emission price | 0.7 CHF |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | CHF |
Technical Indicators
| Highest since issue | 1.15 CHF |
|---|---|
| Lowest since issue | 0.72 CHF |
| Spread | 0.03 CHF |
| Spread % | 2.54% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
807.4
USD
Average target price
850.8
USD
Spread / Average Target
+5.37%
- Stock Market
- Warrants
- LLYI8U Warrant
